LINKED-HEARTS: A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities

Sponsor
Johns Hopkins University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05321368
Collaborator
National Institute on Minority Health and Health Disparities (NIMHD) (NIH)
600
2
47

Study Details

Study Description

Brief Summary

The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hypertension (BP ≥ 140/90 mm Hg) AND either type 2 diabetes or chronic kidney disease (CKD) across 16 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors and will be managed by the patients' primary care clinicians as usual; and (2) the "intervention arm" which will integrate HBPM telemonitoring, a CHW intervention and provider-level interventions into the usual clinical care to improve BP control and provide support for self-management of chronic conditions. The study pharmacist will conduct telehealth, use the Sphygmo app and the Pharmacist Patient Care Process to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: LINKED-HEARTS Program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Anticipated Study Start Date :
Sep 30, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: LINKED-HEARTS Program

Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data. Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources. The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control.

Behavioral: LINKED-HEARTS Program
The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

No Intervention: Enhanced Usual Care

Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.

Outcome Measures

Primary Outcome Measures

  1. Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure [12 months]

    Percent of patients with controlled Blood Pressure (<140/90 mm Hg).

Secondary Outcome Measures

  1. Change in Systolic Blood Pressure [Baseline and 12 months]

    Change from baseline in mean systolic blood pressure in millimeters of mercury (mmHg).

  2. Change in Diastolic blood pressure [Baseline and 12 months]

    Change from baseline in diastolic blood pressure in mmHg.

  3. Mean change in Hemoglobin A1c [Baseline and 12 months]

    Mean change from baseline in hemoglobin A1c (percent) in patients with a diagnosis of diabetes.

  4. Percent with Hemoglobin A1c < 7.0 [Baseline and 12 months]

    Change from baseline in the percent with hemoglobin A1c < 7.0 in patients with a diagnosis of diabetes.

  5. Change in Body Mass Index (BMI) [Baseline and 12 months]

    Change from baseline in BMI (Kg/m^2).

  6. Mean change in Estimated Glomerular Filtration Rate [Baseline and 12 months]

    Mean change from baseline in Estimated Glomerular Filtration Rate.

  7. Change in Health-Related Quality of Life as assessed by the PROMIS 29 [12 months and 24 months]

    This outcome will be measured using Patient-Reported Outcomes Measurement Information System®, (PROMIS) 29 Profile v. 2.0

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. 18 years of age as of date of data extraction,

  2. Self-identify as non-Hispanic white, non-Hispanic Black/African American and/or Hispanic,

  3. Diagnosis of Hypertension (HTN) defined by International Classification of Diseases, Tenth code (ICD-10 code) and elevated systolic blood pressure (SBP) measure (≥140 mm Hg) on their most recent clinic visit.

  4. Diagnosis of diabetes or chronic kidney disease (both defined by ICD-10 code), in addition to HTN

  5. Receives primary medical care at one of the participating health systems

Exclusion Criteria:
  1. Age <18 years

  2. Diagnosis of end-stage renal disease (ESRD) treated with dialysis

  3. Serious medical condition which either limits life expectancy or requires active management (e.g., cancer)

  4. Cognitive impairment or other condition preventing participation in the intervention

  5. Upper arm circumference >50 cm (maximum limit of the extra-large BP cuff)

  6. Active alcohol or substance use disorder (i.e., not sober/abstinent for ≥ 30 days)

  7. Pregnant or planning pregnancy in the next 24 months

  8. Currently nursing a child

  9. Current participation in another research study focused on reducing BP

  10. Current participation in a care management program related to health conditions (e.g., hypertension, diabetes, weight reduction, smoking cessation)

  11. Planning to leave the practice or move out of the geographic area in 24 months

  12. No longer consider the practice site their location for primary care

  13. Unwillingness to provide informed consent

  14. Diagnosis of depression

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Johns Hopkins University
  • National Institute on Minority Health and Health Disparities (NIMHD)

Investigators

  • Principal Investigator: Yvonne Commodore-Mensah, PhD, MSH, RN, JHU School Of Nursing

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT05321368
Other Study ID Numbers:
  • IRB00311760
First Posted:
Apr 11, 2022
Last Update Posted:
Aug 11, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 11, 2022